Physical Therapists in Orange, NJ Accepting Medicare

7 Physical Therapists found. Showing 1 - 7

Donabel Cinco Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 458 Lincoln Ave, A1, Orange, NJ 07050 Phone: 973-673-5610

M. P. Nisperos, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 517 Central Ave Ste 1, Orange, NJ 07050 Phone: 973-414-1357

Activa Rehabilitation Services Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 331 Central Avenue, 1, Orange, NJ 07050 Phone: 973-673-4600    Fax: 973-673-4606

Orange Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 517 Central Ave, Orange, NJ 07050 Phone: 973-414-1357    Fax: 973-414-0713

Kimberly J. Jeanty, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 514 Joyce St, Orange, NJ 07050 Phone: 570-730-5333

Moradeyo Rachael Oluwakuyide, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 514 Joyce St, Orange, NJ 07050 Phone: 973-414-1357

Shawnell Henry, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 493 Valley St Apt 16, Orange, NJ 07050 Phone: 973-738-7673

News Archive

Research provides better understanding of zinc deficiency-induced peripheral neuropathy

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) is honoring Favio C. Bumanlag, BA, with the 2018 Technologist Member Recognition Award for his abstract, Clinical, Laboratory, and Electrodiagnostic Features of Zinc Deficiency-induced Peripheral Neuropathy.

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

Healthcare workers show general apathy towards the flu vaccination

Low flu vaccination rates among healthcare workers could be risking the lives of frail elderly patients and increasing winter pressures in UK hospitals, according to research published in the latest issue of Journal of Clinical Nursing.

Study investigates combined effects of cancer therapy and inherited genetics

Scientists at St. Jude Children's Research Hospital are studying the combined effect of cancer treatments and inherited mutations in DNA-repair genes.

Read more Medical News

› Verified 6 days ago